Xenon Pharmaceuticals Inc.
196 articles about Xenon Pharmaceuticals Inc.
-
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
4/16/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.
-
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4/10/2024
Xenon Pharmaceuticals Inc. today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024.
-
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
4/4/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024.
-
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
3/12/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event.
-
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
3/5/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/29/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
2/22/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2023 financial and operating results after the close of U.S. financial markets on Thursday, February 29, 2024.
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
1/8/2024
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, outlined progress within its pipeline programs and key milestones for 2024.
-
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.
-
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/4/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.
-
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
12/2/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society.
-
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
11/30/2023
Xenon Pharmaceuticals Inc. announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement.
-
Despite a recent Phase II miss, Xenon Pharmaceuticals is forging ahead with its candidate for major depressive disorder, offering 8.4 million common shares for sale.
-
Xenon Pharmaceuticals Announces Proposed Public Offering - November 29, 2023
11/29/2023
Xenon Pharmaceuticals Inc. announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement.
-
While XEN1101 failed to hit the primary endpoint in a Phase II trial, the Canadian company is “actively exploring” further development of the program based on the totality of the data.
-
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
11/27/2023
Xenon Pharmaceuticals Inc. today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD.
-
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine BiosciencesPhase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency
11/9/2023
Xenon Pharmaceuticals Inc. announced that its partner, Neurocrine Biosciences, Inc., reported that the Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures failed to demonstrate meaningful reduction in seizure frequency.
-
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/8/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
11/1/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023.
-
Patients treated with Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 experienced a significant and dose-dependent reduction in seizure frequency.